Trial Profile
A Phase II study of eFT508 in patients already receiving an FDA-approved anti-PD-1 or anti-PD-L1 checkpoint inhibitor (Keytruda, Opdivo, Tecentriq, Bavencio or Imfinzi) alone
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2018
Price :
$35
*
At a glance
- Drugs Tomivosertib (Primary) ; Atezolizumab; Avelumab; Durvalumab; Nivolumab; Pembrolizumab
- Indications Head and neck cancer; Liver cancer; Non-small cell lung cancer; Solid tumours; Urogenital cancer
- Focus Therapeutic Use
- 27 Jul 2018 According to an Effector Therapeutics media release, the company has dosed the first patient in the trial.
- 27 Jul 2018 Status changed from planning to recruiting, as reported in an Effector Therapeutics media release
- 18 Apr 2018 New trial record